These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 27739924)

  • 1. Broadly neutralizing antibodies: An approach to control HIV-1 infection.
    Yaseen MM; Yaseen MM; Alqudah MA
    Int Rev Immunol; 2017 Jan; 36(1):31-40. PubMed ID: 27739924
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antiviral Therapy by HIV-1 Broadly Neutralizing and Inhibitory Antibodies.
    Zhang Z; Li S; Gu Y; Xia N
    Int J Mol Sci; 2016 Nov; 17(11):. PubMed ID: 27869733
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Broadly neutralizing anti-HIV-1 monoclonal antibodies in the clinic.
    Caskey M; Klein F; Nussenzweig MC
    Nat Med; 2019 Apr; 25(4):547-553. PubMed ID: 30936546
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Of Mice, Macaques, and Men: Broadly Neutralizing Antibody Immunotherapy for HIV-1.
    Nishimura Y; Martin MA
    Cell Host Microbe; 2017 Aug; 22(2):207-216. PubMed ID: 28799906
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Harnessing Antibody-Dependent Cellular Cytotoxicity To Control HIV-1 Infection.
    Abuharfeil NM; Yaseen MM; Alsheyab FM
    ACS Infect Dis; 2019 Feb; 5(2):158-176. PubMed ID: 30525453
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Broadly Neutralizing Antibodies for HIV Eradication.
    Stephenson KE; Barouch DH
    Curr HIV/AIDS Rep; 2016 Feb; 13(1):31-7. PubMed ID: 26841901
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Trispecific broadly neutralizing antibodies for HIV immunoprophylaxis and immunotherapy?].
    Barin F; Stefic K
    Med Sci (Paris); 2018 Feb; 34(2):109-111. PubMed ID: 29451475
    [No Abstract]   [Full Text] [Related]  

  • 8. Antibody-mediated prevention and treatment of HIV-1 infection.
    Gruell H; Klein F
    Retrovirology; 2018 Nov; 15(1):73. PubMed ID: 30445968
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Focus on the therapeutic efficacy of 3BNC117 against HIV-1: In vitro studies, in vivo studies, clinical trials and challenges.
    Liu ZJ; Bai J; Liu FL; Zhang XY; Wang JZ
    Int Immunopharmacol; 2017 Nov; 52():44-50. PubMed ID: 28858725
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enhanced HIV-1 immunotherapy by commonly arising antibodies that target virus escape variants.
    Klein F; Nogueira L; Nishimura Y; Phad G; West AP; Halper-Stromberg A; Horwitz JA; Gazumyan A; Liu C; Eisenreich TR; Lehmann C; Fätkenheuer G; Williams C; Shingai M; Martin MA; Bjorkman PJ; Seaman MS; Zolla-Pazner S; Karlsson Hedestam GB; Nussenzweig MC
    J Exp Med; 2014 Nov; 211(12):2361-72. PubMed ID: 25385756
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunotherapy for HIV Infection.
    Weiss RA
    N Engl J Med; 2014 Jan; 370(4):379-80. PubMed ID: 24450898
    [No Abstract]   [Full Text] [Related]  

  • 12. Adeno-Associated Viral Vector Mediated Expression of Broadly- Neutralizing Antibodies Against HIV-Hitting a Fast-Moving Target.
    Sherpa C; Le Grice SFJ
    Curr HIV Res; 2020; 18(2):114-131. PubMed ID: 32039686
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preventive and therapeutic features of broadly neutralising monoclonal antibodies against HIV-1.
    Jaworski JP; Cahn P
    Lancet HIV; 2018 Dec; 5(12):e723-e731. PubMed ID: 30245003
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New-Generation High-Potency and Designer Antibodies: Role in HIV-1 Treatment.
    Gama L; Koup RA
    Annu Rev Med; 2018 Jan; 69():409-419. PubMed ID: 29029583
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Broadly Neutralizing Antibodies for HIV-1 Prevention or Immunotherapy.
    Caskey M; Klein F; Nussenzweig MC
    N Engl J Med; 2016 Nov; 375(21):2019-2021. PubMed ID: 27959740
    [No Abstract]   [Full Text] [Related]  

  • 16. Broadly Neutralizing Antibodies for Human Immunodeficiency Virus Treatment: Broad in Theory, Narrow in Reality.
    Waters L; de Miguel-Buckley R; Poulin S; Arribas JR
    Clin Infect Dis; 2023 Mar; 76(6):1136-1141. PubMed ID: 36303321
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Perspectives for immunotherapy: which applications might achieve an HIV functional cure?
    Vieillard V; Gharakhanian S; Lucar O; Katlama C; Launay O; Autran B; Ho Tsong Fang R; Crouzet J; Murphy RL; Debré P
    Oncotarget; 2016 Jun; 7(25):38946-38958. PubMed ID: 26950274
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Broadly neutralizing antibodies for HIV-1: efficacies, challenges and opportunities.
    Liu Y; Cao W; Sun M; Li T
    Emerg Microbes Infect; 2020; 9(1):194-206. PubMed ID: 31985356
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Towards HIV-1 remission: potential roles for broadly neutralizing antibodies.
    Halper-Stromberg A; Nussenzweig MC
    J Clin Invest; 2016 Feb; 126(2):415-23. PubMed ID: 26752643
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The potential of engineered antibodies for HIV-1 therapy and cure.
    Grobben M; Stuart RA; van Gils MJ
    Curr Opin Virol; 2019 Oct; 38():70-80. PubMed ID: 31421319
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.